Founded in 2021, HoneyBear Biosciences, Inc is a Taiwan-based biotech company with a vision for global pharmaceutical market. We strive to develop new antibody technologies to bring novel therapeutics to the cancer patients.
Our business strategy is to utilize our powerful platform to develop and commercialize novel Antibody-Drug Conjugates (ADC) through licensing and co-development partnership with biotech or pharmaceutical companies.
Our vision
We explore science and technology to discover and develop innovative antibody therapeutics for the cancer patients.
Our mission
We deliver meaningful life to every cancer patient today and challenge tomorrow’s every impossible.
Our values
Innovation, integrity, responsibility
Professional and experienced international management team
We have an excellent management team with diverse and international experiences, accumulating more than 20 years of academic, research and industrial experiences, respectively.
We’re equipped with independent research and development, as well as manufacturing know-how expertise, to form a strong and well collaborative team.
Our leadership team
Edward Wang
Chairman & President
Former Vice Chairman-Petrochemical Industry Association of Taiwan
Former President-USI Corporation and CPDC
Simon Shih-Hsien Chuang
CEO
Inventor of trimannosyl platform technology
Co-founder of HoneyBear Biosciences
Sarina Lin
Business Development VP S.
Exec Director of Novartis (1996-2020) Expertise in commercial excellence
Carol Huang
Manufacturing VP
Exec Director of Amgen and VP of Five Prime Therapeutics
Expertise in antibody manufacture and CMC strategics
Michael Evans
Scientific co-founder
UCSF Professor, Department of Radiology & Biomedical Imaging
Expertise in Radiotherapy & Imaging
Weichyun Wong
CMC consultant and major investor
Chairman and CEO of SCI PHARMTECH
Expertise on API manufacture and CMC
